Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01502358 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01502358: Completed Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
NCT01502358 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01502358, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a new investigational dengue vaccine is safe, well-tolerated, and to see if an immune response against dengue disease will be generated.
Primary Outcome
All AEs and SAEs will be recorded during the entire duration of the study, or up to 360 days.
Interventions
- BIOLOGICAL Tetravalent Dengue Vaccine (TVDV)
- BIOLOGICAL Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)
- BIOLOGICAL Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
What the finished NCT01502358 record still lists
NCT01502358 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 3 interventions - of which Tetravalent Dengue Vaccine (TVDV) is the first listed.
NCT01502358 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01502358 about?
NCT01502358 is a clinical study titled "Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease". The purpose of this study is to determine whether a new investigational dengue vaccine is safe, well-tolerated, and to see if an immune response against dengue disease will be generated.
What is the current status of trial NCT01502358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2011-12. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01502358?
The interventions under investigation include: Tetravalent Dengue Vaccine (TVDV) (BIOLOGICAL), Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose) (BIOLOGICAL), Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01502358?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01502358's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia